Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 20/20 | 0.65 |
| ▸ | PGR | P06401 | 3/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036414 | 0.88 | AR (0.65) | ARPGRNR3C2 | |
| SCHEMBL7036460 | 0.86 | AR (0.65) | ARPGRNR3C2 | |
| SCHEMBL7037188 | 0.84 | AR (0.63) | ARPGRNR3C2 | |
| SCHEMBL7038715 | 0.79 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL7032596 | 0.79 | AR (0.62) | ARPGRNR3C2 | |
| SCHEMBL7037891 | 0.77 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL7038975 | 0.75 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL7035373 | 0.74 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL7036949 | 0.74 | AR (1.00) | ARPGRNR3C2 | |
| SCHEMBL14409341 | 0.73 | AR (0.64) | ARPGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | HAMANN LAWRENCE G (US) | 2003-08-07 | — | — | US | claimed |
| US-6667313-B1 | High affinity and specificity | LIGAND PHARMACEUTICALS INC. | 2003-12-23 | — | — | US | disclosed |
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | HAMANN LAWRENCE G (US) | 2003-08-07 | — | — | US | disclosed |
| EP-1212322-A2 | 8-SUBSTITUTED-6-TRIFLUOROMETHYL-9-PYRIDO[3,2-G]QUINOLINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016133-A2 | 8-SUBSTITUTED-6-TRIFLUOROMETHYL-9-PYRIDO[3,2-G]QUINOLINE COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149268-A1 | 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators | AR, SHBG, NR5A1 | AR 1/4885PGR 32/4885NR3C2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.